The company has predicted that Imaavy — now approved for myasthenia gravis — could eventually earn more than $5 billion in ...

OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod ...

The FDA granted fast track designation to urcosimod to treat neuropathic corneal pain, according to a press release from Okyo Pharma. Urcosimod, formerly called OK-101, is a “lipid conjugated chemerin ...

House Bill 1168 would make it a felony for anyone other than a prescribing physician to “traffic” any drug known to be ...

The potential dangers of these food dyes have been spoken about for years. Here's everything parents need to know.

The FDA also has given tentative approval for rivaroxaban, in dosage strengths of 10 mg, 15 mg and 20 mg. The market value for all of the strengths of rivaroxaban tablets is approximately $8.5 ...

Urcosimod phase 2 trial treating Neuropathic Corneal Pain ("NCP”) patients was initiated in October 2024 and designed as a ...

Marks, who previously led the FDA’s Center for Biologics Evaluation ... followed by New Mexico with 51 cases and Oklahoma with at least 10. A child also reportedly died from measles recently ...

FBN: One FDA change we’re not hearing as much about ... I think what companies have done now is say, “OK, we’ve got 30 months, we have other fires to put out. We’ll deal with this a ...

Former Playboy star Kendra Wilkinson revealed that she started taking a weight-loss drug but threw the medication away after ...

A Blue Cross Blue Shield policy will force some patients to self-inject medicine, with potentially dangerous results.

Oral hormone therapy may benefit heart health in menopausal women. A new analysis of data from the Women's Health Initiative found that estrogen-based oral hormone therapy had a long-term beneficial ...